But there are no hard facts, and a Ligand obligation clouds future licensing economics.

Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.

Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.

Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.

First-in-human trial initiations feature Interius, Umoja and Vironexis.

Western data on EO-3021 fail to live up to the billing of a Chinese trial.